纤维蛋白原 FGEN 深 沪
已收盘 01-07 16:00:00 美东时间
9.71
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 9.71
- 总市值 3928.08万
- 52周最高 21.9375
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 4.85
- 委 比 0.00%
- 总股本 404.54万
- 历史最高 1713.75
- 量 比 0
- 振 幅 0.00%
- 历史最低 4.50
- 每 手 1
- 风险率 2.23%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum
<p>FibroGen, Inc. rebranded to Kyntra Bio, focusing on oncology and rare disease therapies. The company will trade under the new Nasdaq symbol "KYNB" starting January 8, 2026. Kyntra Bio emphasizes its dedication to impactful treatments, with key assets including FG-3246 (CD46-targeting ADC) and roxadustat. Recent milestones include FDA orphan drug designation for roxadustat in myelodysplastic syndromes and planned clinical trial updates for FG-3...
01-07 12:30
FibroGen Wins FDA Orphan Drug Status for Blood Disorder Treatment Roxadustat
FibroGen, Inc. (NASDAQ:FGEN) today announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) has granted roxadustat Orphan Drug Designation for the treatment of
2025-12-15 20:10
FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit
FibroGen, Inc. announced it will attend and present at the Oppenheimer Movers in Rare Disease Summit on December 11, 2025, in New York, NY. Thane Wettig, CEO of FibroGen, will participate in a panel titled "Elevator Pitches from Rare Disease Companies with Key Near-Term, Potentially Stock-Moving Catalysts" at 12:15 PM ET. The company's management team will also be available for one-on-one meetings. FibroGen is focused on developing novel therapie...
2025-12-02 21:05
FibroGen Q3 EPS continuing operations $(3.50) Beats $(4.00) Estimate, Sales $1.076M Miss $1.640M Estimate
FibroGen (NASDAQ:FGEN) reported quarterly losses of $(3.50) per share which beat the analyst consensus estimate of $(4.00) by 12.61 percent. This is a 17.65 percent increase over losses of $(4.25) per share from the same
2025-11-11 05:04
FibroGen Receives $6.4 Million Payment from AstraZeneca
FibroGen ( ($FGEN) ) has provided an announcement. On November 6, 2025, FibroGe...
2025-11-07 05:38
FibroGen to Report Third Quarter 2025 Financial Results
FibroGen, Inc. will announce its third quarter 2025 financial results on November 10 after market close. A conference call and webcast presentation will follow at 5:00 PM Eastern Time, featuring FibroGen's management team discussing the financial results and providing a business update. Interested parties can access the live webcast or register for the call via the links provided. FibroGen, a biopharmaceutical company, focuses on developing novel...
2025-11-03 21:02
美股大行评级 | 217美元！花旗上调阿里巴巴目标价；多家机构集体上调麦克森、美光科技等目标价
今日重点评级关注：Ascendiant Capital：维持Maison Solutions"买入"评级，目标价从4美元升至4.25美元；瑞穗：维持MBX Biosciences"跑赢大市"评级，目标价从38美元升至56美元
2025-09-25 09:52
FibroGen Begins Phase 2 Trial Of New Prostate Cancer Drug FG-3246 With UCSF As First Site
FibroGen, Inc. (NASDAQ:FGEN) today announced the initiation of the Phase 2 monotherapy, dose-optimization trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46-expressing cancer
2025-09-24 19:03
FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer
FibroGen has initiated a Phase 2 dose optimization trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46 in patients with metastatic castration-resistant prostate cancer (mCRPC). The trial will enroll 75 patients and also assess FG-3180, a companion PET imaging agent, as a diagnostic and predictive biomarker. An interim analysis is expected in the second half of 2026. FG-3246 has shown promising clinical activi...
2025-09-24 11:00
FibroGen Completes Sale of FibroGen China to AstraZeneca for Approximately $220 Million
FibroGen announced the successful sale of its China subsidiary to AstraZeneca for approximately $220 million, an increase of $60 million from initial guidance. The transaction includes $85 million in enterprise value and $135 million in net cash. FibroGen also repaid a $81 million term loan to Morgan Stanley Tactical Value, simplifying its capital structure. The sale extends the company's cash runway into 2028. FibroGen plans to initiate a Phase ...
2025-09-02 11:00
